Medicine Access · Access Intelligence · Access Strategy
Approved.
Covered. Still
inaccessible.
Closing the translation gaps between medicine access strategy and real-world treatment initiation.
Medicines fail patients after approval - not because the therapy doesn't work,
but because reimbursement, operational workflows, and patient navigation
never align into one working system.
The core argument
Medicine access does not fail
at one point.
It fails when approval,
reimbursement, pharmacy workflows,
provider actions, and patient navigation
stop translating into one another.
I focus on the translation gap.
Perspective shaped by
Regulatory and reimbursement pathway fluency
Health systems analysis and access strategy
Real-world patient access and medicine use insight
Data-informed approaches to access, equity, and outcomes
Medicines can be approved, covered, and still inaccessible.
Patients can qualify for coverage and still face barriers - LU criteria, EAP,
pharmacy adjudication, and patient navigation rarely connect in practice.
Signature framework
The Medicine Access Translation Gap™
In Ontario, a medicine moves through nine operational stages before treatment begins.
Each handoff is a point where access can stall - even after approval and coverage.
From prescription to first dose - a medicine passes through paperwork, approvals and handoffs long after it is approved and covered.
Access rarely fails at one point. It fails at the disconnects between clinical intent, reimbursement, operational delivery, and patient reality.
Here is what that looks like in practice.
01
LU Codes
The Breakdown
Patient qualifies.
The Barrier
LU criteria not understood.
The Result
Delayed treatment initiation.
The Insight
Coverage alone does not create access.
02
Trillium
The Breakdown
Household faces high drug costs.
The Barrier
Deductible and enrollment steps never completed.
The Result
Eligible support goes unclaimed.
The Insight
A funded programme is not a used programme.
03
PSP Onboarding
The Breakdown
Therapy approved; PSP available.
The Barrier
Consent and coordination stall.
The Result
First dose slips by weeks.
The Insight
The bridge to treatment becomes the bottleneck.
04
Prior Authorization
The Breakdown
Drug is covered.
The Barrier
Clinical justification cycles back and forth.
The Result
Approval arrives after it was needed.
The Insight
Covered is not the same as authorized.
05
Pharmacy Workflow Burden
The Breakdown
Script reaches the counter.
The Barrier
No one owns the access paperwork.
The Result
Pharmacy absorbs invisible hours.
The Insight
Access labour lands on whoever is last in line.
06
Coverage Awareness
The Breakdown
Funding already exists for the patient.
The Barrier
No one tells them they qualify.
The Result
Out-of-pocket cost, or the script is abandoned.
The Insight
Unknown coverage is the same as no coverage.
Perspective
This work comes from seeing systems from the inside.
"Access programmes fail when clinical evidence, regulatory strategy, reimbursement realities, and patient experience are understood in isolation instead of as one connected system."
- Tendai Bbosa
The question I ask first
"At which handoff does the patient's reality stop being visible to decision-makers?"
Identifying the exact handoff is the first step to fixing it.
Regulatory lens
"Is this compliance protecting patients, or protecting the organisation from audit?"
Clinical grounding makes the difference legible.
Access barriers lens
"What does this policy look like on the ground at 3pm in an under-resourced facility?"
I've managed programmes across 3,500+ facilities. I know what breaks at scale.
Approval Is Not Access: Why Canadian Patients Still Wait for Medicines After Regulatory Success
Canada has one of the world's most rigorous regulatory systems for medicines. Yet approval alone does not guarantee that patients will receive timely access to treatment.
Regulatory submissions written by people who've never dispensed a drug have a tell.
When clinical content is disconnected from the regulatory container, the downstream consequences are real: HCP misalignment, patient safety gaps, adoption barriers.
Why the biggest skills gap in access teams isn't scientific - it's operational
The capability gap isn't regulatory or scientific - it's the ability to model how access strategy interacts with real-world healthcare delivery before execution begins.
What managing medicine supply across 3,500 facilities teaches you that no course will
At scale, access barriers have a consistent anatomy: misaligned incentives, data that means different things to different functions, and policy designed without operational input.
I'm a pharmacist and health systems strategist focused on improving medicine
access. Having worked across pharmacy, medicine supply systems, public health
programs, regulatory environments, and healthcare operations, I've seen
how medicines can be approved, covered, and clinically appropriate, yet still
fail to reach patients.
The Medicine Access Translation Gap™ (MATG) is my framework for identifying
and addressing the barriers that stand between medicines and the people who
need them.
Medicine AccessReimbursement PathwaysAccess StrategyPharmacy OperationsHealth Systems
What I help improve
01
Earlier identification of access barriers
Understanding where strategies break operationally before execution begins - not after launch.
02
Better alignment across healthcare functions
Connecting clinical, operational, regulatory, and patient-facing realities so decisions account for downstream consequences.
03
More realistic access execution
Designing with real-world system constraints in mind - evidence-informed iteration from the design stage.
04
Improved adoption and delivery performance
Access strategies that account for provider workflows and patient pathway realities consistently outperform those that don't.
Building the future of medicine access intelligence.
Interested in medicine access, reimbursement strategy, access intelligence, or health systems innovation? Let's connect.
